Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Uvax Bio.

    Client Virtual Booth

    UVAX BIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Uvax Bio
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Newark, DE 19702
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.uvaxbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/uvax-bio/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Uvax Bio Announces Dosing of First Participant in Phase 1 Clinical Trial Evaluating Two Vaccines to Prevent HIV-1 Infection

    Details:

    UVAX-1107 is a novel protein nanoparticle vaccine candidate, which is currently being evaluated in phase 1 clinical trials for the treatment of HIV-infection.


    Lead Product(s): UVAX-1107

    Therapeutic Area: Infections and Infectious Diseases Product Name: UVAX-1107

    Highest Development Status: Phase IProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 30, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Uvax Bio Receives Approval to Initiate a Phase 1 Clinical Trial of Novel HIV-1 Protein Nanoparticle Vaccine Candidates in Australia

    Details:

    UVAX-1107 is a vaccine drug candidate, which is currently being evaluated for the treatment of patients suffering from human immuno deficiency (HIV-1) infection.


    Lead Product(s): UVAX-1107

    Therapeutic Area: Infections and Infectious Diseases Product Name: UVAX-1107

    Highest Development Status: IND EnablingProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 19, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    minakem-m-2024-05-27

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search